Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Moxetumomab Pasudotox |
Anti-CD22 Pseudomonas Exotoxin Immunotoxin | Hematologic (Leukemia) | ||
|
Molecule
Moxetumomab Pasudotox
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
Anti-CD22 Pseudomonas Exotoxin Immunotoxin |
||||
Sugemalimab |
Anti-PD-L1 Monoclonal Antibody | Solid Tumour | ||
|
Molecule
Sugemalimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 Monoclonal Antibody |
||||
Tabelecleucel |
Allogeneic EBV-Specific T-Cell Immunotherapy | Hematologic | ||
|
Molecule
Tabelecleucel
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Allogeneic EBV-Specific T-Cell Immunotherapy |
||||
Zevorcabtagene Autoleucel |
Autologous Anti-BCMA CAR-T Cell Therapy | Hematologic (Multiple Myeloma) | ||
|
Molecule
Zevorcabtagene Autoleucel
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Autologous Anti-BCMA CAR-T Cell Therapy |
||||
Acasunlimab |
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist | Solid Tumour | ||
|
Molecule
Acasunlimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist |
||||
Alisertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Alisertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Anetumab Ravtansine |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Anetumab Ravtansine
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Arlocabtagene Autoleucel |
Autologous Anti-GPRC5D CAR-T Cell Therapy | Hematologic (Multiple Myeloma) | ||
|
Molecule
Arlocabtagene Autoleucel
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Autologous Anti-GPRC5D CAR-T Cell Therapy |
||||
AT7519 (CDK Inhibitor) |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
AT7519 (CDK Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
AZD4547 (Investigational FGFR) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
AZD4547 (Investigational FGFR)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Barasertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Barasertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Bavituximab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Bavituximab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Moxetumomab PasudotoxTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
Anti-CD22 Pseudomonas Exotoxin Immunotoxin |
|
SugemalimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 Monoclonal Antibody |
|
TabelecleucelCellular Therapy |
|
|
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Allogeneic EBV-Specific T-Cell Immunotherapy |
|
Zevorcabtagene AutoleucelCellular Therapy (CAR-T) |
|
|
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Autologous Anti-BCMA CAR-T Cell Therapy |
|
AcasunlimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist |
|
AlisertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
Anetumab RavtansineTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Arlocabtagene AutoleucelCellular Therapy (CAR-T) |
|
|
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Autologous Anti-GPRC5D CAR-T Cell Therapy |
|
AT7519 (CDK Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
AZD4547 (Investigational FGFR)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
BarasertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
BavituximabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|